Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Day (June 2026)
55 slides from Astrazeneca's investor day presentation, Jun 8, 2026
Slide 1: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber, EVP and President, BioPharmaceuticals Sharon Barr, EVP, BioPharmaceuticals R&D Investor Day • 2024
Slide 2: Forward looking statements
Forward looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements wit
Slide 3: Addressing an escalating burden for people, health systems and society
Addressing an escalating burden for people, health systems and society The most prevalent Escalating with ageing Overwhelming health chronic diseases populations systems and economies 2bn+ estimated to 1 in 6 24m deaths each year aged 60+ by 20305 have chronic from chronic diseases* 1-3 diseases7 To
Slide 4: BioPharmaceuticals – transforming the care of chronic diseases
BioPharmaceuticals – transforming the care of chronic diseases Therapy area leadership Industry-leading portfolio Strong growth delivered Growing medicines BioPharmaceuticals medicines Total Revenue #1 in cardiorenal medicine $18.4bn $12.8bn Leadership in asthma and transforming COPD Recent NME laun
Slide 5: BioPharmaceuticals – next wave of growth to 2030 and beyond
BioPharmaceuticals – next wave of growth to 2030 and beyond Illustrative only, not to scale Launching NMEs Beyond 2030 baxdrostat dapa FDCs Amyloidosis combinations to address full spectrum tozorakimab of disease Existing portfolio IVX-A12 Weight management and risk factors Expanding modalities in r
Slide 6: Critical trends transforming BioPharmaceuticals care
Critical trends transforming BioPharmaceuticals care Expanding modalities 1 Disruptive innovations to transform care Early diagnosis 12 Intervening before disease progression to drive better outcomes Novel combinations 13 Dual mechanisms of action to treat interconnected disease Disease modification
Slide 7: Advancing new areas and next-generation therapeutics
Advancing new areas and next-generation therapeutics Expanding modalities Novel combinations Disease modification Building amyloidosis Weight management Treat with curative intent leadership and risk factors in auto-immune diseases • Silencer – Wainua • oGLP-1 – AZD5004 • Cell therapy monotherapy an
Slide 8: Selected key BioPharmaceuticals pipeline catalysts
Selected key BioPharmaceuticals pipeline catalysts 2024 2025 2025+ Fasenra ORCHID Saphnelo IRIS | DAISY AZD0780 (oPCSK9) PURSUIT Wainua CARDIO-TTRansform Phase III chronic rhinosinusitis Phase III lupus nephritis | Phase IIb dyslipidemia Phase III ATTR-CM with nasal polyps Phase III systemic scleros
Slide 9: Cardiovascular, Renal and Metabolism
Cardiovascular, Renal and Metabolism Mina Makar, SVP, Global CVRM Martin Cowie, Interim SVP Late-Stage Development, CVRM Investor Day • 2024
Slide 10: CVRM 2023 Total Revenue >$10bn, leadership in cardiorenal
CVRM 2023 Total Revenue >$10bn, leadership in cardiorenal Delivering double-digit growth Farxiga annualising >$6bn and established as year-on-year foundational care across HF, CKD and T2D CVRM Total Revenue ($m) Farxiga Total Revenue ($m) Heart Type-2 11,000 failure diabetes 7,000 10,000 9,000 6,000
Slide 11: Focus on CVRM diseases where burden remains
Focus on CVRM diseases where burden remains $101bn ATTR-CM 300-500k1 Hypertension 1.3bn2,3 Dyslipidaemia 2bn4 market potential 7% CAGR 2-5yr average mortality post-diagnosis 2 ~50% treated are uncontrolled 4 70% not at LDL-C goal despite statins 6 Cardiovascular $18bn Heart failure with CKD 30m1 CKD
Slide 12: Strong portfolio of novel mechanisms and combinations
Strong portfolio of novel mechanisms and combinations Eliminate HF Reduce hospitalisations Prevent and slow and reverse and reduce CV risk kidney failure obesity-driven from HTN and comorbidities dyslipidaemia Featured new medicines by 2030 Wainua baxdrostat balcinrenone/dapa AZD5004 zibotentan/dapa
Slide 13: Wainua – launch in polyneuropathy unlocks significant opportunity in cardiomyopathy
Wainua – launch in polyneuropathy unlocks $5bn+* significant opportunity in cardiomyopathy Wainua – only monthly approved self-administered PN therapy ATTR-PN up to 40k patients with NEURO-TTRansform9 ATTRv-PN1,2 Favours Wainua End-diastolic volume mean (mL) Launch progressing well in US Stroke volu
Slide 14: Evaluating Wainua in largest ATTR-CM trial to assess different sub-populations
Evaluating Wainua in largest ATTR-CM trial to assess different sub-populations Wainua Phase III CARDIO-TTRansform trial Week 0 Week 140 Week 160 eplontersen | 45mg s.c. Q4W CARDIO-TTRansform N = 1438 history of heart failure due to Open-label extension period or post-treatment evaluation period ATTR
Slide 15: Leveraging CVRM and Rare Disease expertise in ATTR-CM
Leveraging CVRM and Rare Disease expertise in ATTR-CM Complementary mechanisms % NYHA I NYHA II NYHA III NYHA IV population 9% 49% 36% 6% Pathophysiology Medicine and modality less severe more severe 1 TTR Silencer production Wainua – Cardio-TTRansform with data 2025+ Wainua blocks TTR in the liver
Slide 16: baxdrostat – new potential treatment for aldosterone dysregulation, a key driver of hypertension
$5bn+ baxdrostat – new potential treatment for franchise* aldosterone dysregulation, a key driver of hypertension Elevated aldosterone leads Significant reduction in systolic 1.3bn patients with to HTN, CKD and HF blood pressure in Phase IIb hypertension Higher aldosterone leads to BrigHTN Phase IIb
Slide 17: AZD0780 (oPCSK9) – for dyslipidaemia in high-risk cardiovascular disease
AZD0780 (oPCSK9) – for dyslipidaemia in high-risk $5bn+* cardiovascular disease Late-breaker AZD0780 – differentiated target profile session 70% of patients with cardiovascular Oral small Potential disease not at LDL-C target, molecule ≥50% 90% Phase IIb despite high-intensity statins1 enables FDCs
Slide 18: Novel dual mechanisms with dapagliflozin in Phase III
Novel dual mechanisms with dapagliflozin in Phase III balcinrenone/dapagliflozin baxdrostat/dapagliflozin zibotentan/dapagliflozin HF w/ CKD CKD CKD w/ HTN CKD w/ HP Liver cirrhosis BalanceD-HF Phase III MIRO-CKD Phase IIb BaxDUO ARCTIC ZENITH High ZEAL Phase IIb Phase III Proteinuria Phase III 12 m
Slide 19: balcinrenone/dapagliflozin – potential to improve outcomes for patients with HF and CKD
balcinrenone/dapagliflozin – potential to $3-5bn* improve outcomes for patients with HF and CKD Traditional MRAs MIRACLE Phase IIb8:: reduced UACR 45% of HF patients increase hyperkalaemia4-7 without hyperkalaemia have CKD1, of which 75% are not on an MRA2,3 balci/dapa (15/10 mg) balci/dapa (50/10 m
Slide 20: baxdrostat/dapagliflozin – potential to further slow progression of chronic kidney disease
baxdrostat/dapagliflozin – potential to $5bn+* further slow progression of chronic kidney disease BrigHTN Phase II UACR reduction4 Phase III programme ongoing 600m people with CKD and hypertension1,2 placebo baxdrostat Faster decline in renal 0.5mg 1mg 2mg function with higher BaxDuo-ARCTIC >2025 -1
Slide 21: zibotentan/dapagliflozin – to delay worsening of kidney function and prevent liver disease complications
zibotentan/dapagliflozin – to delay worsening of $3-5bn* kidney function and prevent liver disease complications ETA/SGLT2 – complementary Reduced albumin in 10% CKD with high mechanisms ZENITH-CKD Phase IIb6 proteinuria1 123m liver cirrhosis, ~5-10% zibo/dapa (1.5/10mg) zibo/dapa (0.25/10mg) dapa (
Slide 22: Going beyond obesity to improve quality of weight loss and manage comorbidities
Going beyond obesity to improve quality of weight loss and manage comorbidities overweight obese 63% of comorbidities to be targeted by our Population (millions) >50% of global oral and injectable combinations2 population will be overweight or 1,914 988 obese by 20351 2,091 48.2m patients have 82.2m
Slide 23: Delivering durable weight loss, addressing cardiometabolic risk and protecting organs
Delivering durable weight loss, addressing cardiometabolic risk and protecting organs Obesity Overweight T2D (± other severe (+ organ (± obesity/ co-morbidities) protection) overweight) AZD5004 AZD5004 AZD5004 oGLP-1 oGLP-1 oGLP-1 AZD6234 Potential combinations Potential combinations LA amylin AZD95
Slide 24: Three high potential assets progressing to Phase IIb
$5bn+* Three high potential assets progressing to Phase IIb AZD5004 AZD6234 AZD6234 + AZD9550 oGLP-1 long-acting amylin long-acting amylin + GLP-1/glucagon • Selective amylin agonist • Small molecule • Once-weekly dosing • Triple peptide agonists • Strong target engagement • Adjunct for additional f
Slide 25: Multiple high-value opportunities and rich near-term catalyst path support growth to 2030 and beyond
Multiple high-value opportunities and rich near-term catalyst path support growth to 2030 and beyond Growth drivers to 2030 2025 2025+ $5bn+ PYR* baxdrostat Wainua baxdrostat/dapa BaxHTN CARDIO-TTRansform BaxDuo-ARCTIC Phase III HTN Phase III ATTR-CM Phase III CKD with HTN baxdrostat franchise AZD07
Slide 26: Respiratory and Immunology
Respiratory and Immunology Pablo Panella, SVP, Global R&I Caterina Brindicci, SVP Late-Stage Development R&I Investor Day • 2024
Slide 27: Strong growth anticipated in chronic respiratory disease market
Strong growth anticipated in chronic respiratory disease market ~$50bn market by 20307 COPD 91m1 3rd 0 GR 6% C A patients leading cause of biologics approved ~$50bn by 2030 death2,3 in COPD ~$32bn Asthma 93m1 ~50% ~20% patients of severe patients biologics- by 2030 remain penetration in uncontrolled
Slide 28: R&I portfolio poised for accelerated growth through 2030
R&I portfolio poised for accelerated growth through 2030 Transformed portfolio Strong fundamentals support growth Total Revenue ($bn) Multiple recent launches with no major LoE impact before 2030 Substantial opportunity in China and Emerging Markets ex-China Industry-leading pipeline in 2018 2020 20
Slide 29: Industry-leading asthma and COPD portfolio, emerging pipeline
Industry-leading asthma and COPD portfolio, emerging pipeline potential to lead in the pre-biologic market Inhaled Pre-biologic1 Biologic Primary care-led Specialty care-led + COPD Asthma AZD8630 other LCM Phase I iTSLP FAb2 + COPD + COPD other LCM tozorakimab + asthma + other LCM Phase III COPD IL-
Slide 30: Breztri – continues to accelerate with potential to become standard-of-care in COPD
Breztri – continues to accelerate with potential to become $3–5bn* standard-of-care in COPD Breztri is fastest growing FDC triple to become FDC triple mainstay in COPD1 Additional growth drivers Total Revenue ($m) FDC triple share of inhaled Significant opportunity in China 800 maintenance market +7
Slide 31: THARROS – first trial to explore impact of triple therapy on cardiopulmonary outcomes in COPD
THARROS – first trial to explore impact of triple therapy on cardiopulmonary outcomes in COPD, potential to expand eligible population Mortality reduction in CV events significantly higher Potential to expand triple use Phase III ETHOS trial1 following COPD exacerbation2 up to +24m eligible patients
Slide 32: Severe uncontrolled asthma: substantial market growth potential
Severe uncontrolled asthma: substantial market growth potential Sustained growth in biologic-penetration; significant opportunity for further category growth Strong potential for greater 50% 50% 46% biologic-penetration in asthma 45% 40% ~3x increase 35% in severe asthma biologic-penetration 30% in
Slide 33: Fasenra – leading the IL-5 class, expanding in China and LCM unlocking further growth potential
$3–5bn* Fasenra – leading the IL-5 class, expanding in China and LCM unlocking further growth potential Expanding into China with unprecedented efficacy Phase III LCM unlocks >$1bn PYR* opportunity Fasenra Phase III MIRACLE data in China1 ORCHID H2 2024 -74% chronic rhinosinusitis with data readout
Slide 34: Tezspire – set to lead in severe uncontrolled asthma with new growth catalysts through LCM
Tezspire – set to lead in severe uncontrolled asthma with Multi-billion $* new growth catalysts through LCM Early launch success supports establishing Tezspire Upcoming LCM provides leadership in severe uncontrolled asthma additional opportunity US Japan 45% 40% 45% 35% 40% 35% 32% Phase III DIRECTI
Slide 35: Tezspire – new data demonstrate broader potential in COPD
Tezspire – new data demonstrate broader potential in COPD Significant opportunity in COPD1 Tezspire Phase IIa COURSE data in COPD2 Fasenra, dupilumab and mepolizumab studied in high-EOS COPD (EOS ≥300 3 -37% in AER cells/μL) [~30% of market] Primary subgroup analysis: Annual exacerbation rate (AER)
Slide 36: AZD8630 (inhaled anti-TSLP) – potential to extend Tezspire franchise beyond severe asthma
AZD8630 (inhaled anti-TSLP) – potential to extend Tezspire franchise beyond severe asthma with first-ever inhaled biologic Further biologics-penetration AZD8630 Phase Ib data2 – reduced FeNo consistent with Tezspire expansion beyond systemic biologics Percent change from baseline -23% in FeNO Compar
Slide 37: tozorakimab – potential to serve broad population in COPD with ambitious LCM programme
$3–5bn* tozorakimab – potential to serve broad population in COPD with ambitious LCM programme Suppresses activity of both Broadest potential in COPD Robust Phase III programme IL-33red and IL-33ox1 vs other biologics2 Damage Potential across all EOS levels Phase III LUNA programme >2025 IL-33red IL
Slide 38: Expanding in immunology with focus in rheumatology, starting with systemic lupus erythematosus (SLE)
Expanding in immunology with focus in rheumatology, starting with systemic lupus erythematosus (SLE) Significant opportunity in SLE and adjacent diseases Addressing unmet need at each stage of the patient journey Up to Moderate/severe Refractory remission rate for 30% approved biologics1,2 Earlier u
Slide 39: Saphnelo – to become standard of care in SLE and expand into other type I interferon-driven diseases
$1–3bn* Saphnelo – to become standard of care in SLE and expand into other type I interferon-driven diseases New remission data gives New subcutaneous formulation Significant expansion confidence in SLE and geographic expansion beyond SLE, >$1bn PYR* s.c. formulation represents Post-hoc remission1 a
Slide 40: Driving next-generation cell therapy with curative potential
Driving next-generation cell therapy with curative potential CD19 CAR-T provides proof-of-concept in Accelerating our growing ambition autoimmune disease (refractory SLE)1 in Immunology 25 Autologous CAR-T CD19/BCMA Individual patient Refractory SLE trial (China): IIT ongoing 20 data shown (n = 8) A
Slide 41: Multiple high-value opportunities and rich near-term catalyst path support growth to 2030 and beyond
Multiple high-value opportunities and rich near-term catalyst path support growth to 2030 and beyond Six key growth drivers to 2030 2024 2025 Fasenra Breztri ORCHID KALOS | LOGOS Phase III chronic Phase III asthma rhinosinutis with nasal polyps Fasenra Fasenra NATRON RESOLUTE Phase III hyper eosinop
Slide 42: Vaccines and Immune Therapies
Vaccines and Immune Therapies Iskra Reic, EVP, V&I Mark Esser, VP, Early V&I R&D Investor Day • 2024
Slide 43: A strategic adjacency – protecting the vulnerable patients we serve
A strategic adjacency – protecting the vulnerable patients we serve BEY sipavibart – COVID-19 protection for immunocompromised Beyfortus – RSV protection for all infants • sipavibart demonstrated statistically significant reduction in the incidence of symptomatic COVID-19 in immunocompromised patien
Slide 44: Icosavax – innovative and unique vaccine technology
Icosavax – innovative and unique vaccine technology IVX-A12 – a virus-like particle vaccine for RSV and hMPV1 Phase III ready with potential to be IVX-121 IVX-241 RSV hMPV First First First RSV vaccine for combination VLP vaccine for hMPV vaccine for RSV respiratory hMPV viruses IVX-A12 RSV/hMPV biv
Slide 45: RSV and hMPV – significant burden on healthcare systems and patients, especially for older people
RSV and hMPV – significant burden on healthcare systems and patients, especially for older people RSV + hMPV burden is Older people are RSV and hMPV are two leading comparable to COVID-19/flu particularly vulnerable causes of pneumonia Hospitalisations per 10,0005 These viruses can also exacerbate 5
Slide 46: Vaccinations for older adults are an established market and a growing opportunity
$1-3bn* Vaccinations for older adults are an established market and a growing opportunity Older adult vaccinations have Growing opportunity RSV + hMPV is a established treatment driven by ageing population fitting combination pathways and unmet need “Advisory Committee on Immunization Practices (ACI
Slide 47: Investor Day • 2024
Investor Day • 2024
Slide 48: Differentiated profile enabled by VLP platform technology
Differentiated profile enabled by VLP platform technology Phase II data validates VLP technology Robust immune responses against RSV and hMPV Immune responses across age groups, including 70 to 85 years Durable responses with elevated titers retained after 180 days No requirement for adjuvant to boo
Slide 49: Differentiated profile enabled by VLP platform technology
Differentiated profile enabled by VLP platform technology Phase II data validates VLP technology IVX-A12 – targeting a competitive profile Robust immune responses against RSV and hMPV Combination Coverage against RSV and hMPV Strong response in >60 years Immune responses across age Immunogenicity an
Slide 50: IVX-A12 – a unique vaccine with significant opportunity
IVX-A12 – a unique vaccine with significant opportunity Potential first-in-class RSV-hMPV combination vaccine Targeting 2027 season launch $1-3bn PYR potential Acronym definitions can be found in Glossary. Investor Day • 2024
Slide 51: BioPharmaceuticals – delivering on our strategy to unlock the next phase of growth
BioPharmaceuticals – delivering on our strategy to unlock the next phase of growth 2023 2030 2030+ $18.4bn New indications and NMEs New modalities and novel BioPharmaceuticals combinations Total Revenue Five blockbuster medicines Potential ~10 new blockbusters Amyloidosis combinations Weight managem
Slide 52: Q&A session
Q&A session Pascal Soriot Ruud Dobber Sharon Barr C EO , AS T RAZEN EC A EVP, B IO PH ARMAC EUT IC AL S EVP, B IO PH ARMAC EUT IC AL S R& D Iskra Reic Mina Makar Martin Cowie EVP, V& I S VP, GL O B AL C VRM IN T ERIM S VP, L AT E C VRM Regina Fritsche Elisabeth Björk Pablo Panella S VP, EARL Y C VRM
Slide 53: Appendix
Appendix 53 Investor Day • 2024
Slide 54: Glossary – 1 of 2
Glossary – 1 of 2 1L, 2L, 3L first-, second-, third-line CLL chronic lymphocytic leukaemia GLP-1/glu glucagon-like peptide 1 receptor/glucagon dual peptide agonist 6MWT 6-minute walk test cm centimetre GLP-1RA glucagon-like peptide 1 receptor agonist AAV adeno-associated virus CM cardiomyopathy gMG
Slide 55: Glossary – 2 of 2
Glossary – 2 of 2 K+ potassium NST neoadjuvant systemic treatment RSV respiratory syncytial virus KCCQ Kansas City Cardiomyopathy Questionnaire NT-proBNP N-terminal pro-B-type natriuretic peptide s. asthma severe asthma LA amylin long-acting amylin NYHA New York Heart Association s.c. subcutaneous L